Immunotherapeutic Approaches

  • Ryuya¬†Yamanaka

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 746)

Table of contents

  1. Front Matter
    Pages i-xix
  2. Basic and Clinical Aspects of Glioma

    1. Front Matter
      Pages 1-1
    2. Tomotoshi Marumoto, Hideyuki Saya
      Pages 2-11
    3. Nader Sanai, Mitchel S. Berger
      Pages 12-25
    4. Derek R. Johnson, Susan M. Chang
      Pages 26-40
  3. Glioma Immunology

    1. Front Matter
      Pages 41-41
    2. Ian F. Parney
      Pages 42-52
    3. Cleo E. Rolle, Sadhak Sengupta, Maciej S. Lesniak
      Pages 53-76
    4. Masahiro Toda
      Pages 77-84
  4. Cytokine, Serotherapy, Adoptive Transfer And Other Strategies

    1. Front Matter
      Pages 85-85
    2. Masasuke Ohno, Atsushi Natsume, Toshihiko Wakabayashi
      Pages 86-94
    3. Eiichi Ishikawa, Shingo Takano, Tadao Ohno, Koji Tsuboi
      Pages 109-120
    4. Kevin S. Chen, Duane A. Mitchell
      Pages 121-141
  5. Active Immunotherapy

    1. Front Matter
      Pages 142-142
    2. Dong-Sup Chung, Chang-Hyun Kim, Yong-Kil Hong
      Pages 143-150
    3. Terry Lichtor, Roberta P. Glick
      Pages 151-165
    4. Shuichi Izumoto
      Pages 166-177
    5. Ryuya Yamanaka, Koji Kajiwara
      Pages 187-200
  6. Novel Topics

    1. Front Matter
      Pages 201-201
    2. Hiroaki Ikeda, Hiroshi Shiku
      Pages 202-215
    3. Qijin Xu, Xiangpeng Yuan, John S. Yu
      Pages 216-225
  7. Back Matter
    Pages 227-232

About this book


Treatment of glioma is currently one of the most challenging problems in oncology, as well as in neurosurgery. Despite major advances in our understanding of the pathomechanism, diagnosis by imaging and the availability of powerful therapeutic tools, the life expectancy of patients with glioblastoma has only been slightly prolonged and a cure remains elusive. None of the currently available surgical tools, including operative microscopes, lasers and image-guided surgery, can enable the detection and removal of all of the tumor tissue. In recent years, however, the landscape has been changing immeasurably, and molecular studies over the past two decades have identified a variety of genetic aberrations that are specifically associated with individual types of gliomas. In addition, certain molecular abnormalities have been linked to therapy responses, thereby establishing clinical biomarkers and molecular targets, and the use of novel agents is being investigated. These agents have been specifically engineered to exert specific cytotoxicity against gliomas, either on their own as single agents or in combination with other modalities. Moreover, there has been an enormous surge of interest in the area of immunology and immunotherapy, which has been facilitated by our understanding of the molecular basis of gliomas. Although several kinds of immunotherapeutic trials have been undertaken, we still await a great breakthrough in terms of clinical efficacy to prolong the survival time of glioma patients.


Glioma Immunotherapeutic Approaches Neurosurgery Oncology Ryuya Yamanaka

Editors and affiliations

  • Ryuya¬†Yamanaka
    • 1
  1. 1.Kyoto Prefectural University of MedicineKyotoJapan

Bibliographic information

Industry Sectors
Health & Hospitals
Consumer Packaged Goods